子宫内膜癌的风险分层与分子异质性及TIM-3表达谱:一项回顾性队列研究
该回顾性队列研究对628例子宫内膜癌患者实施ProMisE分子分型及风险分组,检测p53、MMR、TIM-3和CD8蛋白表达并对128个癌症相关基因测序。2021 ESGO/ESTRO/ESP风险分层整合分子分型后,11例(1.8%)因p53abn特征升级、23例(3.7%)因POLEmut特征降级。RAD51B突变与p53wt亚型不良无复发生存显著相关;MMRd或POLEmut患者可能从抗TIM-3免疫治疗中获益最多。
要点
- 628例中POLEmut占6.9%、MMRd占18.8%、p53abn占11%、p53wt占63.3%。
- 2021分子整合风险分层使11例(1.8%)升级、23例(3.7%)降级。
- TIM-3在免疫细胞中表达率30.9%、肿瘤细胞中29.0%,POLEmut和MMRd中更常见。
核心结论
- 研究揭示了子宫内膜癌各亚型及亚组间的分子异质性,新风险分层系统因整合分子特征改变了部分患者的风险分组。
- RAD51B突变可进一步对p53wt亚型的复发风险进行分层。
- MMRd或POLEmut患者可能从抗TIM-3免疫治疗中获益最多。
研究设计与样本
- 回顾性队列研究,纳入628例子宫内膜癌患者。
- 采用免疫组化检测p53、MMR、TIM-3和CD8蛋白表达,并对128个癌症相关基因进行大规模平行测序。
- 按ProMisE分为MMRd、POLEmut、p53wt和p53abn四个亚型并进行风险分类。
主要发现
- 43例(6.9%)为POLEmut,118例(18.8%)为MMRd,69例(11%)为p53abn,398例(63.3%)为p53wt。
- 与2016分层系统相比,2021 ESGO/ESTRO/ESP风险分层整合分子分型后,11例(11/628,1.8%)因p53abn特征升级,23例(23/628,3.7%)因POLEmut特征降级。
- JAK1和RAD50突变在侵袭性表型患者中频率较高。
- RAD51B突变与p53wt亚型的不良无复发生存显著相关,但在其他三个分子亚组中无此关联。
- TIM-3在免疫细胞中表达率为30.9%、在肿瘤细胞中为29.0%,且在肿瘤细胞和免疫细胞中POLEmut和MMRd较其他两个分子亚型更常表达。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The present study aimed to implement ProMisE classification and risk grouping on a retrospective cohort of 628 patients with endometrial cancer (EC) and determine the molecular heterogeneity across subtypes and subgroups, as well as to investigate the potential beneficiary for TIM-3 checkpoint inhibition in ECs. METHODS: Protein expressions of p53, MMR, TIM-3 and CD8 were measured by immunohistochemistry, and massively parallel sequencing was conducted for 128 cancer-related genes. Patients were categorized into four ProMisE subtypes: MMR-deficient (MMRd), POLE-ultramutated (POLEmut), p53-wild type (p53wt), and p53-abnormal (p53abn), and were subjected to risk classification. RESULTS: 43 (6.9%) patients belonged to POLEmut, 118 (18.8%) to MMRd, 69 (11%) to p53abn, and 398 (63.3%) to p53wt. Compared to the 2016 stratification system, the 2021 ESGO/ESTRO/ESP risk stratification integrated with molecular classification revealed that 11 patients (11/628, 1.8%) were upgraded due to the p53abn signature, whereas 23 patients (23/628, 3.7%) were downgraded due to the POLEmut signature. JAK1 and RAD50 mutations showed higher frequencies in patients with aggressive phenotypes. RAD51B mutation was significantly related to poor RFS of the p53wt subtype but not of the other three molecular subgroups. TIM-3 expression was detected in 30.9% immune cells (ICs) and 29.0% tumor cells (TCs) in ECs, respectively. It was frequently expressed in POLEmut and MMRd ECs as compared to that in the other two molecular subtypes in TCs and ICs. CONCLUSIONS: Our study revealed the molecular heterogeneity across subtypes and subgroups. The new risk stratification system changed the risk grouping of some patients due to the integration of molecular features. RAD51B mutation can further stratify the recurrence risk in the p53wt subtype. Patients with MMRd or POLEmut may benefit most from immunotherapy against TIM-3.
引用
- Zhang Y, Yang R, Xu C, et al. Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study. Gynecol Oncol. 2023. PMID: 36709662. doi:10.1016/j.ygyno.2023.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。